Systemic treatment of metastatic breast cancer: SABCS 2018

被引：1

作者：

Westphal, Theresa ^{[1
]}

Gampenrieder, Simon Peter ^{[1
]}

Greil, Richard ^{[1
]}

机构：

[1] Paracelsus Med Univ, Dept Internal Med Haematol Med Oncol Haemostaseol, SCRI LIMCR, Canc Cluster,Oncol Ctr, Salzburg, Austria

来源：

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2019年 / 12卷 / 03期

关键词：

San Antonio Breast Cancer Symposium; Highlights; Review; IMpassion130; SOLAR-1;

D O I：

10.1007/s12254-019-00517-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review summarizes clinically relevant trials in metastatic breast cancer (MBC) presented at the 2018 San Antonio Breast Cancer Symposium (SABCS). At the meeting updates of two large phase III studies were presented: (1) the biomarker analysis of IMpassion130, trying to define the target population for the checkpoint inhibitor atezolizumab in triple-negative MBC and (2) a subgroup analysis of SOLAR-1, where the efficacy and safety of the alpha-specific Phosphoinositide 3(PI3)-kinase inhibitor alpelisib in combination with fulvestrant was investigated in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) MBC. Furthermore, we review the results of a randomized phase II trial (CCTG MA38) comparing a continuous daily dosing of palbociclib to the standard treatment dose, and the phase 1b data of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax in combination with tamoxifen as a novel drug combination in patients with HR+/HER2-MBC.

引用

页码：253 / 256

页数：4

共 14 条

[1] Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer [J].

Abdollahpour-Alitappeh, Meghdad ;

Lotfinia, Majid ;

Bagheri, Nader ;

Sepehr, Koushan Sineh ;

Habibi-Anbouhi, Mahdi ;

Kobarfard, Farzad ;

Balalaie, Saeed ;

Foroumadi, Alireza ;

Abbaszadeh-Goudarzi, Ghasem ;

Abbaszadeh-Goudarzi, Kazem ;

Abolhassani, Mohsen .

JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) :2693-2704

[2]

[Anonymous], 2019, Cancer Res, DOI [DOI 10.1158/1538-7445.SABCS18-GS1-04, 10.1158/1538-7445.SABCS18-GS1-04]

[3] Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. [J].

Baselga, Jose ;

Dent, Susan Faye ;

Cortes, Javier ;

Im, Young-Hyuck ;

Dieras, Veronique ;

Harbeck, Nadia ;

Krop, Ian E. ;

Verma, Sunil ;

Wilson, Timothy R. ;

Jin, Huan ;

Wang, Lijia ;

Schimmoller, Frauke ;

Hsu, Jerry Y. ;

He, Jing ;

DeLaurentiis, Michelino ;

Drullinsky, Pamela ;

Jacot, William .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)

[4] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[5] PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer [J].

Crowder, Robert J. ;

Phommaly, Chanpheng ;

Tao, Yu ;

Hoog, Jeremy ;

Luo, Jingqin ;

Perou, Charles M. ;

Parker, Joel S. ;

Miller, Melinda A. ;

Huntsman, David G. ;

Lin, Li ;

Snider, Jacqueline ;

Davies, Sherri R. ;

Olson, John A., Jr. ;

Watson, Mark A. ;

Saporita, Anthony ;

Weber, Jason D. ;

Ellis, Matthew J. .

CANCER RESEARCH, 2009, 69 (09) :3955-3962

[6] Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer [J].

Ethier, J-L ;

Parulekar, W. ;

Shepherd, L. ;

Summers, L. ;

Strasser-Weippl, K. ;

Tu, D. ;

Amir, E. .

CANCER RESEARCH, 2019, 79 (04)

[7] Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer [J].

Hwang, Ki-Tae ;

Han, Wonshik ;

Kim, Jongjin ;

Moon, Hyeong-Gon ;

Oh, Sohee ;

Song, Yun Seon ;

Kim, Young A. ;

Chang, Mee Soo ;

Noh, Dong-Young .

JOURNAL OF BREAST CANCER, 2017, 20 (01) :54-64

[8] Alpelisib plus fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial [J].

Juric, D. ;

Ciruelos, E. ;

Rubovszky, G. ;

Campone, M. ;

Loibl, S. ;

Rugo, H. S. ;

Iwata, H. ;

Conte, P. ;

Mayer, I. A. ;

Kaufman, B. ;

Yamashita, T. ;

Lu, Y-S ;

Inoue, K. ;

Takahashi, M. ;

Papai, Z. ;

Longin, A-S ;

Mills, D. ;

Wilke, C. ;

Sellami, D. ;

Andre, F. .

CANCER RESEARCH, 2019, 79 (04)

[9] Beyond B cells: Targeting BCL-2 pro-sruvival proteins in breast cancer [J].

Lindeman, G. .

CANCER RESEARCH, 2019, 79 (04)

[10] A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer [J].

Mayer, Ingrid A. ;

Abramson, Vandana G. ;

Formisano, Luigi ;

Balko, Justin M. ;

Estrada, Monica V. ;

Sanders, Melinda E. ;

Juric, Dejan ;

Solit, David ;

Berger, Michael F. ;

Won, Helen H. ;

Li, Yisheng ;

Cantley, Lewis C. ;

Winer, Eric ;

Arteaga, Carlos L. .

CLINICAL CANCER RESEARCH, 2017, 23 (01) :26-34

← 1 2 →